Telomere maintenance as a target for anticancer drug discovery

Maintenance of telomeres — specialized complexes that protect the ends of chromosomes — is undertaken by the enzyme complex telomerase, which is a key factor that is activated in more than 80% of cancer cells that have been examined so far, but is absent in most normal cells. So, targeting telomere-maintenance mechanisms could potentially halt tumour growth across a broad spectrum of tumour types, with little cytotoxic effect outside tumours. Here, we describe the current understanding of telomere biology, and the application of this knowledge to the development of anticancer drugs.

[1]  D. Corey,et al.  Telomerase inhibition by peptide nucleic acids reverses `immortality' of transformed human cells , 1999, Oncogene.

[2]  E. Blackburn,et al.  Telomere fusions caused by mutating the terminal region of telomeric DNA. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[3]  D. Sun,et al.  G-quadruplex DNA binding by a series of carbocyanine dyes. , 2001, Bioorganic & medicinal chemistry letters.

[4]  June Corwin,et al.  Telomerase Catalytic Subunit Homologs from Fission Yeast and Human , 1997 .

[5]  J. Mergny,et al.  Fluorescence Resonance Energy Transfer as a Probe for G‐Quartet Formation by a Telomeric Repeat , 2001, Chembiochem : a European journal of chemical biology.

[6]  et al.,et al.  The RNA component of human telomerase , 1995, Science.

[7]  S. Neidle,et al.  Human telomerase inhibition by substituted acridine derivatives. , 1999, Bioorganic & medicinal chemistry letters.

[8]  T. Lange,et al.  Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. , 1998, Science.

[9]  R. Wellinger,et al.  The terminal DNA structure of mammalian chromosomes , 1997, The EMBO journal.

[10]  J. Mergny,et al.  Telomerase inhibitors based on quadruplex ligands selected by a fluorescence assay , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[11]  P. Baumann,et al.  Pot1, the Putative Telomere End-Binding Protein in Fission Yeast and Humans , 2001, Science.

[12]  D. Patel,et al.  Solution structure of the human telomeric repeat d[AG3(T2AG3)3] G-tetraplex. , 1993, Structure.

[13]  O. Fedoroff,et al.  NMR-Based model of a telomerase-inhibiting compound bound to G-quadruplex DNA. , 1998, Biochemistry.

[14]  Bas van Steensel,et al.  Control of telomere length by the human telomeric protein TRF1 , 1997, Nature.

[15]  J. Shay,et al.  Normal human chromosomes have long G-rich telomeric overhangs at one end. , 1997, Genes & development.

[16]  C B Harley,et al.  Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.

[17]  Jiunn-Liang Chen,et al.  Secondary Structure of Vertebrate Telomerase RNA , 2000, Cell.

[18]  David M. Prescott,et al.  Inhibition of telomerase by G-quartet DMA structures , 1991, Nature.

[19]  I. Hickson,et al.  Inhibition of the Bloom's and Werner's syndrome helicases by G-quadruplex interacting ligands. , 2001, Biochemistry.

[20]  M. Hande,et al.  Ku acts in a unique way at the mammalian telomere to prevent end joining. , 2000, Genes & development.

[21]  R. Reddel,et al.  Telomere maintenance by recombination in human cells , 2000, Nature Genetics.

[22]  W. A. Sexton,et al.  STRUCTURE—ACTIVITY RELATIONSHIPS , 1958, The Journal of pharmacy and pharmacology.

[23]  W. Hahn,et al.  Inhibition of telomerase limits the growth of human cancer cells , 1999, Nature Medicine.

[24]  J. W. Turner,et al.  Stable Association of hsp90 and p23, but Not hsp70, with Active Human Telomerase* , 2001, The Journal of Biological Chemistry.

[25]  J. Pines,et al.  Four-dimensional control of the cell cycle , 1999, Nature Cell Biology.

[26]  Bas van Steensel,et al.  TRF2 Protects Human Telomeres from End-to-End Fusions , 1998, Cell.

[27]  R. Dalla‐Favera,et al.  Direct activation of TERT transcription by c-MYC , 1999, Nature Genetics.

[28]  G. Morin,et al.  TANK2, a New TRF1-associated Poly(ADP-ribose) Polymerase, Causes Rapid Induction of Cell Death upon Overexpression* , 2001, The Journal of Biological Chemistry.

[29]  D. Corey,et al.  Identification of determinants for inhibitor binding within the RNA active site of human telomerase using PNA scanning. , 1997, Biochemistry.

[30]  S. Kerwin,et al.  Perylene diimide G-quadruplex DNA binding selectivity is mediated by ligand aggregation. , 2002, Bioorganic & medicinal chemistry letters.

[31]  R. Reddel,et al.  Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines , 1997, Nature Medicine.

[32]  J. Griffith,et al.  Mammalian Telomeres End in a Large Duplex Loop , 1999, Cell.

[33]  Carol W. Greider,et al.  Identification of a specific telomere terminal transferase activity in tetrahymena extracts , 1985, Cell.

[34]  J. Shay,et al.  Telomere Shortening Is Proportional to the Size of the G-rich Telomeric 3′-Overhang* , 2000, The Journal of Biological Chemistry.

[35]  T. Cech,et al.  Telomerase and the maintenance of chromosome ends. , 1999, Current opinion in cell biology.

[36]  S. Neidle,et al.  Structural characterization of a guanine-quadruplex ligand complex. , 2000, Biochemistry.

[37]  S Neidle,et al.  Molecular modeling studies on G-quadruplex complexes of telomerase inhibitors: structure-activity relationships. , 1999, Journal of medicinal chemistry.

[38]  D. Corey,et al.  Inhibition of human telomerase by 2'-O-methyl-RNA. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[39]  N. Maizels,et al.  The Bloom’s Syndrome Helicase Unwinds G4 DNA* , 1998, The Journal of Biological Chemistry.

[40]  B. Druker,et al.  Bcr-Abl inhibition as a modality of CML therapeutics. , 2001, Biochimica et biophysica acta.

[41]  M. Searle,et al.  Recognition and stabilization of quadruplex DNA by a potent new telomerase inhibitor: NMR studies of the 2:1 complex of a pentacyclic methylacridinium cation with d(TTAGGGT)4 , 2001 .

[42]  D. Corey,et al.  Inhibition of telomerase by 2'-O-(2-methoxyethyl) RNA oligomers: effect of length, phosphorothioate substitution and time inside cells. , 2001, Nucleic acids research.

[43]  S. Neidle,et al.  Inhibition of human telomerase by a G-quadruplex-interactive compound. , 1997, Journal of medicinal chemistry.

[44]  Margaret A. Strong,et al.  The Shortest Telomere, Not Average Telomere Length, Is Critical for Cell Viability and Chromosome Stability , 2001, Cell.

[45]  K. Shin‐ya,et al.  Telomestatin, a novel telomerase inhibitor from Streptomyces anulatus. , 2001, Journal of the American Chemical Society.

[46]  T. Simonsson,et al.  G-Quadruplex DNA Structures Variations on a Theme , 2001, Biological chemistry.

[47]  L. Tao.  G-quadruplex DNA: A Potential Target for Anti-cancer Drug Design , 2001 .

[48]  E. Raymond,et al.  Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells. , 1999, Cancer research.

[49]  S. Neidle,et al.  2,7-Disubstituted amidofluorenone derivatives as inhibitors of human telomerase. , 1999, Journal of medicinal chemistry.

[50]  I. Kuntz,et al.  Spectroscopic recognition of guanine dimeric hairpin quadruplexes by a carbocyanine dye. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[51]  S. Neidle,et al.  A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity. , 2002, Molecular pharmacology.

[52]  M. Henriksson,et al.  c-myc Suppression in Burkitt's lymphoma cells. , 2002, Biochemical and biophysical research communications.

[53]  O. Fedoroff,et al.  Induction of Duplex to G-quadruplex Transition in the c-myc Promoter Region by a Small Molecule* , 2001, The Journal of Biological Chemistry.

[54]  D. V. Von Hoff,et al.  Telomerase assay using biotinylated-primer extension and magnetic separation of the products. , 1998, BioTechniques.

[55]  Stephen Neidle,et al.  Structure-based design of selective and potent G quadruplex-mediated telomerase inhibitors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[56]  D. Corey,et al.  Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[57]  J. Mergny,et al.  Ethidium derivatives bind to G-quartets, inhibit telomerase and act as fluorescent probes for quadruplexes. , 2001, Nucleic acids research.

[58]  M. Salazar,et al.  Cleavage of telomeric G-quadruplex DNA with perylene-EDTA*Fe(II). , 2001, Biochemistry.

[59]  J. Campisi,et al.  TIN2, a new regulator of telomere length in human cells , 1999, Nature Genetics.

[60]  Robert A. Weinberg,et al.  Creation of human tumour cells with defined genetic elements , 1999, Nature.

[61]  L. Hurley,et al.  Accelerated assembly of G-quadruplex structures by a small molecule. , 1999, Biochemistry.

[62]  T. Lange,et al.  Identification of Human Rap1 Implications for Telomere Evolution , 2000, Cell.

[63]  N. Kallenbach,et al.  Interaction of the dye ethidium bromide with DNA containing guanine repeats. , 1992, Biochemistry.

[64]  Kazuo Shin-Ya,et al.  Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular g-quadruplex. , 2002, Journal of the American Chemical Society.

[65]  R. Glasspool,et al.  Telomerase and cancer: time to move from a promising target to a clinical reality , 2001, The Journal of pathology.

[66]  D. Broccoli,et al.  p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. , 1999, Science.

[67]  E. Blackburn.  Switching and Signaling at the Telomere , 2001, Cell.

[68]  D. Langley,et al.  Selective interactions of cationic porphyrins with G-quadruplex structures. , 2001, Journal of the American Chemical Society.

[69]  A. Schnapp,et al.  Mechanism of Human Telomerase Inhibition by BIBR1532, a Synthetic, Non-nucleosidic Drug Candidate* , 2002, The Journal of Biological Chemistry.

[70]  D. Bearss,et al.  Telomere maintenance mechanisms as a target for drug development , 2000, Oncogene.

[71]  E. Sahai,et al.  RHO–GTPases and cancer , 2002, Nature Reviews Cancer.

[72]  J. Mergny,et al.  Cell senescence and telomere shortening induced by a new series of specific G-quadruplex DNA ligands , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[73]  R. Weinberg,et al.  hEST2, the Putative Human Telomerase Catalytic Subunit Gene, Is Up-Regulated in Tumor Cells and during Immortalization , 1997, Cell.

[74]  R. Wheelhouse,et al.  Quadruplex-interactive agents as telomerase inhibitors: synthesis of porphyrins and structure-activity relationship for the inhibition of telomerase. , 2001, Journal of medicinal chemistry.

[75]  A. Schnapp,et al.  A highly selective telomerase inhibitor limiting human cancer cell proliferation , 2001, The EMBO journal.

[76]  L. Hurley,et al.  G-quadruplex DNA: a potential target for anti-cancer drug design. , 2000, Trends in pharmacological sciences.

[77]  J. Griffith,et al.  T‐loop assembly in vitro involves binding of TRF2 near the 3′ telomeric overhang , 2001, The EMBO journal.

[78]  M. Stevens,et al.  Potent inhibition of telomerase by small-molecule pentacyclic acridines capable of interacting with G-quadruplexes. , 2001, Molecular pharmacology.

[79]  S. Neidle,et al.  Human telomerase inhibition by regioisomeric disubstituted amidoanthracene-9,10-diones. , 1998, Journal of medicinal chemistry.

[80]  R. Wheelhouse,et al.  Cationic Porphyrins as Telomerase Inhibitors: the Interaction of Tetra-(N-methyl-4-pyridyl)porphine with Quadruplex DNA , 1998 .

[81]  S. Kerwin.  G-Quadruplex DNA as a target for drug design. , 2000, Current pharmaceutical design.